ClinicalTrials.gg
RecruitingNCT05795686Eval-ARRPACUpdated Jun 26, 2024

Evaluation of the Impact of the AVanCer Program Provided by the ARRPAC Day Center

An interventional study of Evaluation of program "AVanCer" in Stroke, Brain Injury and Rehabilitation, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Stroke by Hospices Civils de Lyon — 13 open to participants now, 14 under way, none of them phase 3. Stroke · Hospices Civils de Lyon.

Planned enrollment
8th of 26
162 · median 50
Started
2023
with 3 others
No phase
24 of 40
8 open now
Primary completion
2026-04
later than 2 of 13 live
Registered
29th of 40
by date

Among the 40 studies in Stroke by Hospices Civils de Lyon, this one is the 8th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2023, is one of 24 with no phase, reaches primary completion later than 2 of the 13 other live ones, and was the 29th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

13 of the 40 studies in Stroke by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Stroke by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

In France, more than 150,000 strokes occur each year. Stroke is a major risk factor for dependency, representing the leading cause of acquired non-traumatic disability in adults. Head injuries, which are also very frequent, can leave similar neuropsychiatric sequelae.

These events are brutal and their physical, psychological, emotional, social and financial consequences disrupt the lives of patients and their families. Thanks to improved access to thrombolysis and thrombectomy for the management of acute stroke, the prognosis has been profoundly improved. Nevertheless, the increase in post-stroke survival and the evolution of the type of after-effects require the development of support systems dedicated to these post-stroke patients. The same issues are raised for people who have suffered a head injury with similar consequences that require specialised care.

Currently, health care is well structured for the acute phase and there is an improvement in the provision of care in specialised rehabilitation services, but the dedicated medico-social provision for people returning home remains insufficient despite the significant needs. The ARRPAC association (Accompaniment, Rehabilitation, Respite after Stroke and Cerebral Palsy) is setting up a new comprehensive medico-social support programme in Lyon (AVanCer programme, opening in June 2022) to improve the autonomy and adaptation capacities of patients and to relieve the social and psycho-affective burden of carers. This experimental day centre, which complements functional rehabilitation and recurrence prevention care, offers adults with brain injury sequelae and their carers therapeutic education programmes, adapted physical activity, social and cognitive remediation and therapeutic workshops, as well as a place for patients and their carers to exchange information and listen. To achieve its ambition, ARRPAC and the AVanCer programme must be integrated into the existing support offer, create partnerships with care structures and evaluate its added value to ensure its sustainability. In case of efficiency and demonstrated benefits for patients, carers and the health system, such a structure could be deployed in other territories.

This study evaluates the implementation of the AVanCer programme in terms of its effect on the target audience, participants' experience and implementation according to the REAIM evaluative framework (Reach, Effectiveness, Adoption, Implementation, and Maintenance).

03

Conditions studied

  • Stroke
  • Brain Injury
  • Rehabilitation

Keywords

  • Stroke
  • Brain injury
  • Rehabilitation
  • Autonomy
  • Caregivers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patients :

  • Male or female of legal age
  • Patient who has been selected to start the AVanCer program at the ARRPAC center
  • Patient who has agreed to participate in the PATIENT assessment component and has signed the consent form
  • Patient able to speak and understand French both orally and in writing

For caregivers :

  • Male or female of legal age
  • Person who has agreed to participate in the CAREGIVING assessment component and has signed the consent form
  • Person able to speak and understand French both orally and in writing

Population of the qualitative study :

  • Voluntary patients and caregivers who participated in the quantitative part (follow-up by questionnaires)
  • Partner professionals: a sample of 10 representatives of ARRPAC partners who referred people for support during the first 12 months, from the following structures: public Medicine, Surgery, Obstetric health institution, private Medicine, Surgery, Obstetric health institution, public Follow-up and Rehabilitation Care institution, private Follow-up and Rehabilitation Care institution, medico-social institution, town professionals and user associations.
  • ARRPAC professionals: the 14 ARRPAC professionals involved in the day care centre will be interviewed in a semi-structured manner

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, parturient or breastfeeding mothers*
  • Persons deprived of their liberty by a judicial or administrative decision
  • Persons under psychiatric care
  • Persons admitted to a health or social establishment for purposes other than research
  • Persons of full age subject to a legal protection measure (guardian, curators)
  • Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Other
    Patients of program "AVanCer"

    Patients included in program "AVanCer"

    Other: Evaluation of program "AVanCer"

Interventions

  • OtherEvaluation of program "AVanCer"

    Evaluation of program AVanCer with quantitative and qualitative approaches

06

What researchers measure

Primary outcomes

  1. Goal Attainment Scaling (GAS)

    The GAS will quantify the achievement of the goals set by the patient. It will be calculated at the end of the programme (planned end or premature exit) on the basis of the objectives set when the patient was included in the programme. The objectives and the different steps to reach them are defined in consultation between the patient, the doctor and the nurse. It is a 5-point scale (-2, -1, 0, 1, 2); -2: level before participation, -1: less than expected; 0: expected goal achieved; +1: a little more than expected; +2: best possible outcome expected.

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4)

Secondary outcomes

  1. Quality of life of post-stroke patients measured by SIS (Stroke Impact Scale)

    This is a specific quality of life scale for patients post-stroke. The scale contains 64 items measuring 8 different domains (strength, hand functionality, Activities of Daily Living ADL/ Instrumental Activities of Daily Living IADL, mobility, communication, emotion, memory/thinking and social participation) and one item assessing overall recovery out of 100. The items are scored using a Likert scale with 5 response options. The score is reported out of 100 for each dimension (100 = no difficulties, 0= maximum difficulties)

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

  2. Quality of life of post brain injury patients measured by QOLIBRI (Quality Of LIfe after BRain Injury)

    This is a specific quality of life scale for patients post brain injury. The scale contains 37 items measuring 6 different domains (cognitive, affective, functional, relational, physical and emotional). The items are scored using a Likert scale with 5 response options. The score is reported out of 100 (100 = best quality of life, 0 = worst quality of life)

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

  3. Depression and anxiety measured by HADS (Hospital Anxiety Depression Scale)

    This is a specific depression and anxiety scale of 14 items. The scale contains 14 items of which 7 measure anxiety and 7 measure depression. The items are scored from 0 to 3, giving two scores out of 21 for each dimension; a score above 11 indicates an anxious or depressed state.

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

  4. Autonomy measured by modified Rankin score (mRS)

    This is a validated 6-level global assessment scale. The score is between 0 et 6, a higher score is associated to a worse outcome.

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4)

  5. Walking assessment by 6 MWT (6 Minutes Walking Test)

    This is a functional walking test

    Time frame: End of the program (between Month 2 and Month 4)

  6. Autonomy in health assessed by the PAM-13 (Patient Activation Measure)

    This is a test assessing skills, knowledge and knowledge, skills and confidence in managing one's health. The scale contains 13 items scored on a 4-point Likert scale. The total score is reported out of 100 (100 = maximum activation, 0 = no activation)

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

  7. Adhesion to preventive treatment assessed by the Girerd questionnaire

    This is a specific self-questionnaire that assesses compliance in 6 items. Each item can be answered by yes or no. For each item, "Yes" scores 0 and "No" scores 1. A final score of 0 means a good observance, of 1 or 2 means a mild compliance problem, and of 3 or more means a poor compliance.

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

  8. Quality of life of caregivers measured by SF36 (Short Form Health Survey)

    This is a validated scale measuring health-related quality of life. Score is between 0 and 100, A higher score is associated to a better outcome.

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

  9. Depression and anxiety of caregivers measured by HADS (Hospital Anxiety Depression Scale)

    This is a specific depression and anxiety scale of 14 items. The scale contains 14 items of which 7 measure anxiety and 7 measure depression. The items are scored from 0 to 3, giving two scores out of 21 for each dimension; a score above 11 indicates an anxious or depressed state.

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

  10. Perceived burden of caregivers measured by the Zarit questionnaire

    This is a self questionnaire assessing the suffering of caregivers. Score is between 0 and 88. A higher score is associated to a worse outcome.

    Time frame: Inclusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

  11. Reaching the target population evaluated by : 1- The description of the active file : description of socio-demographic characteristics

    The indicators are obtained from data collected in the user file. The socio-demographic characteristics collected are: age, gender, family status, professional status, social status

    Time frame: Inclusion (Day 0)

  12. Reaching the target population evaluated by : 2-The description of medical characteristics

    The indicators are obtained from data collected in the user file. Medical characteristics are type of stroke, treatment and sequelae

    Time frame: Inclusion (Day 0)

  13. Adoption : 1-Integration in the territory evaluated by the department of residence of patients

    This indicator is obtained from data collected in the user file.

    Time frame: Inclusion (Day 0)

  14. Adoption : 2-Link with partners assessed by way of patient referral

    This indicator is obtained from data collected in the user file. The type of practioner who referred the patient is collected

    Time frame: Inclusion (Day 0)

  15. Adoption : 3-Perception of the structure by professionals

    The perception of the structure will be assessed through semi-structured interviews conducted by the research team. The questions focus on the professional's feelings about their participation in the facility and are 30 minutes long

    Time frame: Through study completion, an average of 22 years

  16. Adoption : 4-Active patient file : number of inclusions per week

    This indicator is obtained from data collected in the user file.

    Time frame: Through study completion, an average of 22 years

  17. Implementation 1-Number of patients present compared to the number of patients planned per activity

    This indicator is obtained from data collected in the user file.

    Time frame: Through study completion, an average of 22 years

  18. Implementation : 2-Follow-up of programs (number of patients per programs)

    The follow-up of programs will be described, for each program, by the number of patients per program over time

    Time frame: Through study completion, an average of 22 years

  19. Implementation : 3-Deployment of therapeutic workshops : description of workshops

    Description of workshops in terms of type of activity , rhythm

    Time frame: End of study (Month 22)

  20. Maintenance: 1-Over time at the organisational level by monitoring team meetings

    Integration into the medico-social offer in the long term via the partnerships established and maintenance of the activities initiated during the program by the patients measured 6 months after the end of the program

    Time frame: End of the program (between Month 2 and Month 4) ; End of study (Month 22)

  21. Maintenance : 2-Evaluation of the sustainability of activities since the end of the program

    One question will focus on the continuation of activities and the description of these activities

    Time frame: 6 months after end of program (between Month 8 and Month 10)

  22. Cost

    Average cost to produce all the support provided by the programme by modelling the pathways

    Time frame: End of study (Month 22)

  23. Assessment of transferability

    Assessment of transferability using the ASTAIRE grid (Analysis of transferability and support for the adaptation of health promotion interventions) : it contains 4 categories of criteria: description of the population (descriptive criteria of the population), environment (environmental factors likely to influence the effects), implementation conditions (elements of implementation of the intervention, particularly with reference to aspects of planning and partnerships) and support for transfer (elements that make it possible to support the transfer of the intervention and contribute in particular to its adaptation to the new context.

    Time frame: End of study (Month 22)

  24. Knowledge of the disease and treatments:

    • Knowledge of the disease and treatments: using a knowledge of the disease and treatments questionnaire

    Time frame: clusion (Day 0) ; End of the program (between Month 2 and Month 4) ; 6 months after the end of the program (between Month 8 and Month 10)

07

Study locations

1 of 1 sites recruiting
  • Accueil de jour ARRPAC
    Bron, 69500, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Apr 2026, 34 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 34 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Apr 3, 2023
StartActual
Jun 20, 2023
Primary completionEst.
Apr 20, 2026
CompletionEst.
Apr 20, 2026
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05795686
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Jun 20, 2023
Primary completion
Apr 20, 2026 (estimated)
Completion
Apr 20, 2026 (estimated)
Last update
Jun 26, 2024

Study contacts

Julie Haesebaert, MD
Contact
julie.haesebaert01@chu-lyon.fr
06-51-42-97-43 ext. +33
Anne Termoz
Contact
anne.termoz@chu-lyon.fr
04-27-85-63-00 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion